Clinical trials: Treatment Resistant Major Depression
Major Depressive Disorder
Targeting IL-17A for Treatment-Resistant Depression
The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).
- Trial name
- NCT04979910
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
DEPRESSION
Efficacy of Intermittent ThetaBurst Stimulation Compared to 10 Hz Stimulation on Dorsolateral Prefrontal Cortex in Treatment Resistant Major Depressive Disorder: a Double-blind Randomized Study
This trial will compare innovating stimulation parameters, intermittent Theta Burst Stimulation, to the standard high frequency stimulation protocol.
- Trial name
- THETA-DEP (NCT02376491)
- Testing
- Transcranial magnetic stimulation
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Nantes University Hospital
Bipolar Disorder
The Treatment of Children and Adolescents With Treatment-Resistant Depression
This study seeks to learn about brain function in adolescents with depression and to determine whether adding lithium carbonate to antidepressant medication can reduce depression in children and adolescents.
- Trial name
- NCT00029640
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment Resistant Depression
Epidural Cortical Stimulation for Depression
Objective: Chronic epidural cortical stimulation (ECS) involves the neurosurgical placement of an electric wire on the surface of the brain with intermittent activation.
- Trial name
- EpCS-D (NCT00565617)
- Testing
- Synergy, Epidural cortical stimulation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Medical University of South Carolina
Treatment Resistant Depression, Major Depressive Disorder
Sustained Mood Improvement With Laughing Gas Exposure: A Randomized Controlled Pilot Trial
The purpose of the study is to investigate a short-term treatment option for major depressive disorders by administering nitrous oxide gas.
- Trial name
- SMILE (NCT04957368)
- Testing
- Nitrous Oxide 99 %, Oxygen + Midazolam
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Unity Health Toronto
Major Depressive Disorder
Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females
The investigators propose to determine if 8 weeks of dietary augmentation with oral 5g creatine monohydrate daily and 100 mg of 5-hydroxytryptophan (5-HTP) twice daily reduces hypoxia-related depressive symptoms measured by the…
- Trial name
- NCT02922725
- Testing
- 5-hydroxytryptophan and Creatine
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Brent Michael Kious, MD, PhD
Major Depression
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S.
- Trial name
- PIVOT (NCT07226232)
- Testing
- Psilocybin
- Where
- 5 sites in United States
- Volunteers
- 240 people
- Sponsor
- VA Office of Research and Development
Depression, Unipolar, Treatment Resistant Depression
PF-04995274 and Emotional Processing in Treatment Resistant Depression
This study will test whether seven days adjunctive administration of a serotonin receptor subtype 4 (5HT4) agonist called PF-04995274 has positive effects on emotional processing and non-emotional cognition in medicated…
- Trial name
- RESTART (NCT03515733)
- Testing
- PF-04995274
- Where
- United Kingdom
- Volunteers
- 54 people
- Sponsor
- University of Oxford
Depressive Disorder, Treatment-Resistant
Adaptive tDCS for Treatment-Resistant MDD
This pilot study aims to investigate the potential role of transcranial direct current stimulation (tDCS) in the treatment of treatment-resistant major depressive disorder (MDD).
- Trial name
- NCT02942368
- Testing
- tDCS
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Magnetic Resonance Imaging, Major Depression
Ketamine Alcohol (in Treatment-Resistant Depression)
A single subanesthetic dose infusion of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has rapid and robust antidepressant effects in patients with treatment-refractory major depressive disorder (TRD).
- Conditions
- Magnetic Resonance Imaging, Major Depression, Alcoholism
- Trial name
- NCT02122562
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mark Niciu
Depression
Buprenorphine for Late-Life Treatment Resistant Depression
The goals of this pilot study are to gather data about the safety and clinical effect of low-dose buprenorphine in older adults with treatment resistant depression.
- Trial name
- BUILD (NCT01071538)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder
Rapid Antidepressant Effects of Leucine
This randomized double-blind placebo-controlled crossover study seeks to evaluate the antidepressant effect of L-leucine, an essential amino acid, in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT03079297
- Testing
- L-Leucine, Maltodextrin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depression
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism
Reduction of volume of the hippocampus has been associated with major depression in many studies. It has been suggested that antidepressants may protect against hippocampus volume loss in humans associated with multiple episodes…
- Trial name
- NCT00704860
- Testing
- Open label pharmacotherapy
- Where
- Canada
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Ottawa
Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD)
Home-Based Randomized Trial of Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression
This study aims to evaluate the clinical efficacy and neurophysiological mechanisms of home-based spaced tDCS in TRD through a randomized, double-blind, sham-controlled trial conducted under remote supervision.
- Trial name
- NCT07834762
- Testing
- Spaced Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of California, San Diego
Suicidal Ideation, Major Depressive Disorder
N2O for Acute Suicidality and Depression in the ED
Investigators are conducting this double-blind, randomized control trial (RCT), to compare inhaled N2O+ treatment as usual (TAU) versus inhaled placebo+TAU; demonstrating the feasibility and tolerability of the intervention in an…
- Conditions
- Suicidal Ideation, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- NCT05710887
- Testing
- Nitrous oxide gas for inhalation
- Where
- United States
- Sponsor
- University of Chicago
Major Depression
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder
Background: Drugs and talk therapy help treat depression, but these treatments usually take quite a bit of time to work. Ketamine is a fast-acting antidepressant, but it has side effects like unusual dreams and experiences.
- Trial name
- NCT02484456
- Testing
- AV 101 (4-Chlorokynurenine)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depression, Generalized Anxiety Disorder
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
The purpose of this study is to explore the changes in metabolic parameters in patients treated with escitalopram for six months for major depression, generalized anxiety disorder or panic disorder, with or without agoraphobia.
- Conditions
- Major Depression, Generalized Anxiety Disorder, Panic Disorder
- Trial name
- NCT00711737
- Where
- Singapore
- Volunteers
- 27 people
- Sponsor
- Changi General Hospital
Psychiatric Disorder, Major Depressive Disorder
Exploring Blood Plasma Metabolomics: Unraveling the Metabolic Landscape in Treatment-Resistant Adolescent Depression
This study contributes new evidence for the identification of adolescent TRD and sheds light on differing pathophysiologies by delineating distinct plasma metabolic profiles between adolescent TRD and FEDN-MDD.
- Conditions
- Psychiatric Disorder, Major Depressive Disorder, Metabolic Disorder
- Trial name
- NCT06331572
- Testing
- 17-HAMD
- Where
- China
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Major Depressive Disorder
Treatment Resistant Geriatric Depression in Primary Care
This study involves collaboration between McLean Hospital, Geriatric Medicine at the Cambridge Health Alliance (CHA) and other sites within the Partners and Harvard Medical School network.
- Trial name
- NCT01392287
- Testing
- Memantine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Treatment Resistant Depression, Major Depressive Disorder
Mechanistic Evaluation of Response in TRD (MERIT)
To evaluate the relapse prevention of AXS-05 relative to placebo in subjects with treatment resistant depression (TRD). This is a randomized, double-blind, placebo-controlled study to evaluate AXS-05 compared to placebo in…
- Trial name
- MERIT (NCT04608396)
- Testing
- AXS-05
- Where
- 20 sites in United States
- Volunteers
- 44 people
- Sponsor
- Axsome Therapeutics, Inc.